Clinical pharmacology and tolerability of REC‐994, a redox‐cycling nitroxide compound, in randomized phase 1 dose‐finding studies

• Main Authors: Ron Alfa (Author), Timothy Considine (Author), Shafique Virani (Author), Matt Pfeiffer (Author), Anthony Donato (Author), Daniel Dickerson (Author), Diana Shuster (Author), Joel Ellis (Author), Kristen Rushton (Author), Helen Wei (Author), Christopher Gibson (Author)
• Format: Book
• Published: Wiley, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Cerebral cavernous malformation (CCM) has variable clinical symptoms, including potentially fatal hemorrhagic stroke. Treatment options are very limited, presenting a large unmet need. REC‐994 (also known as tempol), identified as a potential treatment through an unbiased drug discovery pla...